Vir Biotechnology Inc (VIR)

$22.63 0.37 (1.66%)

15:05 EDT VIR Stock Quote Delayed 30 Minutes

The Top 7 Growth Stocks in Biotech

By Alex Sirois Mar 3, 2023

The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.

The 7 Most Undervalued Biotech Stocks to Buy in February 2023

7 Healthcare Stocks That Will Be Big Winners in 2023

3 Biotech Stocks to Buy Now for Extraordinary Gains

Volume:

Previous Close -

Market Cap 3.02B

PE Ratio 41.15

EPS 0.55

Volume (Avg. Vol.) 417,923

Day's Range $22.01 - $22.68

52-Week Range $18.05 - $31.78

Dividend & Yield N/A (N/A)

VIR Stock Predictions, Articles, and Vir Biotechnology Inc News

From InvestorPlace
From the Web

4 Undervalued Biotech Stocks to Add to Your Buy List

By Shanthi Rexaline Apr 20, 2022

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Mar 30, 2022

Rise and shine, investor! It's time to go over the biggest pre-market stock movers in our breakdown for Wednesday morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Dec 2, 2021

Good morning, trader! We're gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday!

VIR Stock Pops Amid Renewed Omicron Variant Concerns. Here’s Why.

By Samuel O'Brient, InvestorPlace Financial News Writer Nov 30, 2021

Vir Biotechnology has a Covid-19 treatment that its CEO says will do well against new variants. Amid uncertainty, VIR stock is climbing.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Nov 30, 2021

Good morning, investor! We're starting off Tuesday with a breakdown of the biggest pre-market stock movers you need to know about!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Nov 17, 2021

Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday!

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

By Sarah Smith, Editor-in-Chief, InvestorPlace.com Mar 11, 2021

What did the stock market do today? Biden signed the American Rescue Plan, OCGN stock popped and CPNG stock came public.

VIR Stock: Why Vir Biotechnology Is Plunging Today

By Chris MacDonald, InvestorPlace Contributor Mar 3, 2021

VIR stock is plunging on some pretty unfavorable news about a trial being suspended for the company's prospective Covid-19 vaccine.

7 Biotech Stocks to Buy That Could Beat the Coronavirus

By Chris Lau, InvestorPlace Contributor Apr 1, 2020

These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure. Buy them now.

VIR stock gains as JPMorgan upgrades on flu and Hep B candidates (NASDAQ:VIR)

From Seeking Alpha Mar 6, 2023

Vir Biotechnology (VIR) added ~5% pre-market Monday after JPMorgan upgraded the COVID-19 drugmaker citing upcoming data readouts for its flu and Hep B candidates. Read the full story here.

Vir Biotechnology loses 5% following Q4 2022 earnings misses (NASDAQ:VIR)

From Seeking Alpha Feb 24, 2023

Vir Therapeutics (VIR) is down 5% in after-hours trading after its Q4 2022 financial results missed on the top and bottom lines.Year over year, revenue declined ~94% due to...

Vir Biotechnology GAAP EPS of -$0.76 misses by $0.42, revenue of $49.4M misses by $84.84M (NASDAQ:VIR)

From Seeking Alpha Feb 23, 2023

Vir Biotechnology press release (VIR): Q4 GAAP EPS of -$0.76 misses by $0.42.Revenue of $49.4M (-93.9% Y/Y) misses by $84.84M.

Vir stock jumps as Goldman Sachs upgrades to Buy on post-COVID narrative (NASDAQ:VIR)

From Seeking Alpha Feb 21, 2023

Vir Biotechnology (VIR) gained ~9% Tuesday after Goldman Sachs upgraded it to Buy from Hold, citing a post-COVID leg to its story due to its flu vaccine. Read the full story.

VIR stock upgraded at Morgan Stanley on multiple catalysts in 2023 (NASDAQ:VIR)

From Seeking Alpha Jan 27, 2023

Morgan Stanley upgraded COVID-19 drug developer Vir Biotechnology (VIR) on Friday, citing multiple Phase 2 readouts this year targeting infectious diseases. Read the full story here.

2 Stocks That Could Turn $100 Into $1,000 by 2028

From The Motley Fool Jan 22, 2023

These growth stocks have substantial tailwinds.

Vir Biotechnology Inc (VIR)

The Top 7 Growth Stocks in Biotech

The 7 Most Undervalued Biotech Stocks to Buy in February 2023

7 Healthcare Stocks That Will Be Big Winners in 2023

3 Biotech Stocks to Buy Now for Extraordinary Gains

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Vir Biotechnology Inc (VIR)

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

VIR Stock Predictions, Articles, and Vir Biotechnology Inc News

Subscriber Sign in